JP2021535164A5 - - Google Patents
Info
- Publication number
- JP2021535164A5 JP2021535164A5 JP2021511547A JP2021511547A JP2021535164A5 JP 2021535164 A5 JP2021535164 A5 JP 2021535164A5 JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021511547 A JP2021511547 A JP 2021511547A JP 2021535164 A5 JP2021535164 A5 JP 2021535164A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024028682A JP7825650B2 (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862726162P | 2018-08-31 | 2018-08-31 | |
| US62/726,162 | 2018-08-31 | ||
| PCT/US2019/049118 WO2020047447A1 (en) | 2018-08-31 | 2019-08-30 | Cardiac sarcomere inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028682A Division JP7825650B2 (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021535164A JP2021535164A (ja) | 2021-12-16 |
| JP2021535164A5 true JP2021535164A5 (enExample) | 2022-10-18 |
| JP7447089B2 JP7447089B2 (ja) | 2024-03-11 |
Family
ID=67953902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021511547A Active JP7447089B2 (ja) | 2018-08-31 | 2019-08-30 | 心筋サルコメア阻害剤 |
| JP2024028682A Active JP7825650B2 (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024028682A Active JP7825650B2 (ja) | 2018-08-31 | 2024-02-28 | 心筋サルコメア阻害剤 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11414424B2 (enExample) |
| EP (1) | EP3843842A1 (enExample) |
| JP (2) | JP7447089B2 (enExample) |
| KR (1) | KR20210068422A (enExample) |
| CN (2) | CN118955409A (enExample) |
| AR (1) | AR116283A1 (enExample) |
| AU (1) | AU2019328556B2 (enExample) |
| BR (1) | BR112021003496A2 (enExample) |
| CA (1) | CA3110237A1 (enExample) |
| CL (1) | CL2021000481A1 (enExample) |
| CO (1) | CO2021003115A2 (enExample) |
| EA (1) | EA202190657A1 (enExample) |
| EC (1) | ECSP21016009A (enExample) |
| IL (2) | IL315709A (enExample) |
| MA (1) | MA53491A (enExample) |
| MX (1) | MX2021002199A (enExample) |
| NZ (1) | NZ773016A (enExample) |
| PH (1) | PH12021550400A1 (enExample) |
| SG (1) | SG11202101769YA (enExample) |
| TW (1) | TWI848972B (enExample) |
| UY (1) | UY38358A (enExample) |
| WO (1) | WO2020047447A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MA53491A (fr) * | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| US12516016B2 (en) * | 2020-03-11 | 2026-01-06 | Sheldon Cao | GPX4 inhibitors, pharmaceutical compositions thereof, and their use for treating GPX4-mediated diseases |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| JP7700218B2 (ja) * | 2020-09-17 | 2025-06-30 | 浙江海正薬業股▲ふん▼有限公司 | ピペラジン誘導体、その製造方法、およびその使用 |
| WO2022105852A1 (zh) * | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| EP4514355A1 (en) | 2022-04-26 | 2025-03-05 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| RS67793B1 (sr) | 2022-09-02 | 2026-03-31 | Cytokinetics Inc | Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida |
| WO2025096779A2 (en) | 2023-11-01 | 2025-05-08 | Bristol Myers Squibb Company | Methods of treatment with a myosin inhibitor using protein levels |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ES2293638T3 (es) | 1994-03-25 | 2008-03-16 | Isotechnika, Inc. | Mejora de la eficacia de farmacos por deuteracion. |
| US5919785A (en) * | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| KR100595926B1 (ko) | 1998-01-26 | 2006-07-05 | 웨인 웨스터만 | 수동 입력 통합 방법 및 장치 |
| AU2002365057A1 (en) | 2001-12-21 | 2003-07-30 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| ATE552236T1 (de) | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| EP1621540A4 (en) * | 2003-04-21 | 2008-07-23 | Ono Pharmaceutical Co | HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN AND USE THEREOF |
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| JP2008521900A (ja) * | 2004-11-30 | 2008-06-26 | アムジエン・インコーポレーテツド | キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用 |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (ru) * | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| EP4234017B1 (en) | 2015-01-22 | 2026-04-15 | MyoKardia, Inc. | Preparation of 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) |
| JP2019507110A (ja) | 2015-12-17 | 2019-03-14 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物性オキサジアゾール誘導体 |
| CN108368098B (zh) | 2015-12-18 | 2022-01-28 | 先正达参股股份有限公司 | 杀微生物的噁二唑衍生物 |
| WO2017222951A1 (en) | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| WO2018089433A1 (en) * | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2019144041A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| RS65302B1 (sr) | 2019-07-17 | 2024-04-30 | Cytokinetics Inc | Oralne formulacije inhibitora srčanog sarkomera |
| EP3999180B1 (en) | 2019-07-17 | 2024-05-08 | Cytokinetics, Inc. | Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide |
| EP4054588A4 (en) | 2019-11-10 | 2023-12-13 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
| MX2023002024A (es) | 2020-08-28 | 2023-05-10 | Myokardia Inc | Métodos de tratamiento con modulador de miosina. |
| CN114456163B (zh) | 2020-11-09 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114516843B (zh) | 2020-11-19 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| WO2022105852A1 (zh) | 2020-11-20 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN116507621B (zh) | 2020-11-24 | 2025-10-17 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN114539257B (zh) | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| CN114539229B (zh) | 2020-11-24 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| RS67793B1 (sr) | 2022-09-02 | 2026-03-31 | Cytokinetics Inc | Kristalni oblici 5-(3,4-difluorbenzil)-8-((1r,4r)-4-metilcikloheksil)-6,9-diokso-2,5,8-triazapiro[3.5]nonan-2-karbaldehida |
-
2019
- 2019-08-30 MA MA053491A patent/MA53491A/fr unknown
- 2019-08-30 CA CA3110237A patent/CA3110237A1/en active Pending
- 2019-08-30 UY UY0001038358A patent/UY38358A/es active IP Right Grant
- 2019-08-30 BR BR112021003496-0A patent/BR112021003496A2/pt unknown
- 2019-08-30 US US16/557,281 patent/US11414424B2/en active Active
- 2019-08-30 AR ARP190102477A patent/AR116283A1/es unknown
- 2019-08-30 CN CN202410976837.3A patent/CN118955409A/zh active Pending
- 2019-08-30 IL IL315709A patent/IL315709A/en unknown
- 2019-08-30 NZ NZ773016A patent/NZ773016A/en unknown
- 2019-08-30 TW TW108131375A patent/TWI848972B/zh active
- 2019-08-30 CN CN201980068999.4A patent/CN112867539B/zh active Active
- 2019-08-30 EA EA202190657A patent/EA202190657A1/ru unknown
- 2019-08-30 SG SG11202101769YA patent/SG11202101769YA/en unknown
- 2019-08-30 KR KR1020217008799A patent/KR20210068422A/ko active Pending
- 2019-08-30 MX MX2021002199A patent/MX2021002199A/es unknown
- 2019-08-30 EP EP19768990.4A patent/EP3843842A1/en active Pending
- 2019-08-30 JP JP2021511547A patent/JP7447089B2/ja active Active
- 2019-08-30 IL IL281075A patent/IL281075B2/en unknown
- 2019-08-30 WO PCT/US2019/049118 patent/WO2020047447A1/en not_active Ceased
- 2019-08-30 AU AU2019328556A patent/AU2019328556B2/en active Active
-
2021
- 2021-02-25 CL CL2021000481A patent/CL2021000481A1/es unknown
- 2021-02-26 PH PH12021550400A patent/PH12021550400A1/en unknown
- 2021-03-09 EC ECSENADI202116009A patent/ECSP21016009A/es unknown
- 2021-03-10 CO CONC2021/0003115A patent/CO2021003115A2/es unknown
-
2022
- 2022-05-04 US US17/736,895 patent/US11952381B2/en active Active
-
2024
- 2024-02-26 US US18/587,730 patent/US12275741B2/en active Active
- 2024-02-28 JP JP2024028682A patent/JP7825650B2/ja active Active
-
2025
- 2025-01-08 US US19/014,118 patent/US20250276976A1/en active Pending